Mdm2 is the major negative regulator of the p53 pathway. Here, we report that Mdm2 is rapidly degraded after DNA damage and that phosphorylation of Mdm2 by casein kinase I (CKI) at multiple sites triggers its interaction with, and subsequent ubiquitination and destruction, by SCF b-TRCP . Inactivation of either b-TRCP or CKI results in accumulation of Mdm2 and decreased p53 activity, and resistance to apoptosis induced by DNA damaging agents. Moreover, SCF b-TRCP -dependent Mdm2 turnover also contributes to the control of repeated p53 pulses in response to persistent DNA damage. Our results provide insight into the signaling pathways controlling Mdm2 destruction and further suggest that compromised regulation of Mdm2 results in attenuated p53 activity, thereby facilitating tumor progression.
INTRODUCTION
Tumors often arise through gain of function of certain oncogenes concomitantly with loss of key tumor suppressors. The p53 protein is considered an important tumor suppressor because its function is compromised in >50% of human tumors (Hollstein et al., 1991) . The ability of p53 to suppress tumor development is primarily attributed to its activity as a transcription factor that can activate a wide variety of downstream target genes that are responsible for p53-dependent cell-cycle arrest or apoptosis on a variety of cellular stresses (Harms et al., 2004; Levine, 1997) , such as p21 (Bunz et al., 1998; el-Deiry et al., 1993) , Gadd45, 14-3-3 (Chan et al., 1999; Wang et al., 1999) , and Bax (Zhang et al., 2000) . Because of its crucial role in response to DNA damage, p53 is critical for maintaining the integrity of the genome (Daujat et al., 2001; Harper and Elledge, 2007; Levine et al., 2004) .
Due to the important role of p53 in regulating cell proliferation and survival, its activity has to be tightly regulated (Toledo and Wahl, 2006) . In normal unstressed cells, p53 activity must be kept low because inappropriate activation of p53 promotes premature senescence or apoptosis (Blaydes and WynfordThomas, 1998; Mendrysa et al., 2003) . On the other hand, p53 destruction must be quickly disabled to allow for the rapid establishment of the p53 stress response (Toledo and Wahl, 2006) . Central to this regulatory mechanism is the Mdm2 protein,
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a major negative regulator of p53, which promotes p53 ubiquitination and subsequent destruction in unstressed cells (Haupt et al., 1997; Midgley and Lane, 1997) . The N-terminus of the Mdm2 protein interacts with p53 and its C-terminal ring-finger domain, which possesses the ubiquitin E3 ligase activity, ubiquitinates p53 (Kussie et al., 1996) . The importance of Mdm2 in p53 regulation is further illustrated by the fact that the embryonic lethal phenotype in Mdm2 knockout mice can be partially rescued by further inactivation of the p53 protein (Montes de Oca Luna et al., 1995) .
Previous studies showed that binding of Mdm2 to p53 is subject to many layers of regulation. Among them, the DNA damage-induced ATM/ATR/CHK kinase cascade plays a pivotal role. In response to stress such as DNA damage, activation of the ATM/ATR/CHK kinase pathway results in p53 phosphorylation, which disrupts the interaction between Mdm2 and p53, allowing p53 to escape Mdm2-mediated proteolysis and become stabilized (Chehab et al., 2000; Harper and Elledge, 2007; Hirao et al., 2000) . It was reported that in response to DNA damage signals, the Mdm2 protein was quickly degraded (Stommel and Wahl, 2004) , allowing p53 to accumulate and become fully activated. However, the molecular mechanisms still remain unclear. Although it is proposed that Mdm2 undergoes autoubiquitination when cells are challenged with DNA damage agents (Stommel and Wahl, 2004; Stommel and Wahl, 2005) , a recent study using transgenic mice provided definitive evidence that the E3 ligase activity of Mdm2 is not required for the proper destruction of Mdm2 (Itahana et al., 2007) . This suggests that the destruction of Mdm2 is controlled by an as yet unknown pathway. The goal of this study was to delineate the molecular mechanisms governing Mdm2 ubiquitination and destruction.
RESULTS

Mdm2 Stability Is Controlled by b-TRCP
In agreement with previous reports (Itahana et al., 2007; Stommel and Wahl, 2004) , we found that Mdm2 became unstable after DNA damage treatment in various types of cells ( Figure 1A and data not shown). Furthermore, we found that Mdm2 protein abundance fluctuated during the cell cycle ( Figure 1B ). Consistent with a more recent study showing that the E3-ligase activity of Mdm2 is not required for Mdm2 destruction (Itahana et al., 2007) , we found that the degradation of the ring-finger mutant Mdm2 C464A , which is defective in its E3 ubiquitin ligase activity, was still accelerated by a variety of DNAdamaging agents (data not shown). This data suggested that an unknown pathway controls Mdm2 destruction in response to genotoxic stress.
Multisubunit Cullin-Ring complexes comprise the largest known class of E3 ubiquitin ligases (Petroski and Deshaies, 2005) . We first examined whether a specific Cullin-Ring complex is involved in controlling Mdm2 destruction. We found that Mdm2 specifically interacts with Cullin 1, but not other members of the Cullin family we examined ( Figure 1C ). We also detected the interaction between endogenous Mdm2 and endogenous Cullin 1 ( Figure 1D ). Depletion of endogenous Cullin 1 led to an increase in Mdm2 abundance (see Figure S1A available online), indicating that the Cullin 1 pathway might play a role in the regulation of Mdm2 stability. Consistent with that Mdm2 C464A can still be degraded, we found that Mdm2 C464A binds to Cullin 1 as efficiently as wild-type Mdm2 ( Figure S1B ). These data together suggest that the Cullin 1 complex might be the E3 ligase responsible for Mdm2 stability independent of its auto-ubiquitination. Next, we sought to explore which F-box protein complexed with Cullin 1 is responsible for Mdm2 destruction. Because Mdm2 expression fluctuates during the cell cycle ( Figure 1B) , we started our investigation by using a panel of siRNAs targeting different F-box proteins (as well as Cdh1 as a negative control) that have been demonstrated to participate in cell-cycle regulation. We found that depletion of b-TRCP, but not other F-box proteins, led to a significant accumulation of Mdm2 (Figure 1E) . We further found that unlike other reported b-TRCP substrates, such as Cdc25A (Moshe et al., 2004) , inactivation of either b-TRCP1 or b-TRCP2 is sufficient to upregulate Mdm2 ( Figure 1F ; Figure S1C ). Additionally, ectopic expression of b-TRCP1 engineered to resist shTRCP1 or shTRCP1+2 treatment suppressed Mdm2 upregulation ( Figure 1G ; Figure S1D ), indicating that depletion of endogenous b-TRCP might be causative for Mdm2 upregulation. Because depletion of b-TRCP did not increase Mdm2 mRNA level ( Figure 1H ), the observed increase in Mdm2 abundance is mainly through posttranscriptional mechanisms. In support of this idea, using cycloheximide, we demonstrated that the half-life of the endogenous Mdm2 protein was extended after depletion of the b-TRCP1 protein ( Figures 1I and 1J) . Furthermore, b-TRCP-mediated Mdm2 destruction occurred primarily in the late G1-S phase, as indicated by the marked increase in Mdm2 abundance after depletion of b-TRCP in this specific cell-cycle window ( Figure S1E ).
Mdm2
Interacts with b-TRCP1 in a PhosphorylationDependent Manner Consistent with a role for b-TRCP in regulating Mdm2 stability, under ectopic overexpression conditions, Mdm2 interacts with both b-TRCP1 and b-TRCP2 (Figure 2A ). Furthermore, we detected the interaction between endogenous Mdm2 and endogenous b-TRCP1 ( Figure 2B ). The interaction between Mdm2 and b-TRCP1 is largely reduced if the C-terminal WD40 repeats motif of b-TRCP1, which has been shown to mediate the interaction with most of its substrates (Wu et al., 2003) , is mutated ( Figure 2C ). We also found that Mdm2 C464A interacts with b-TRCP1 as well ( Figure S2 ) and that DNA damage treatment enhanced the interaction between endogenous Mdm2 and endogenous b-TRCP1 ( Figure 2D ). In keeping with previous reports (Frescas and Pagano, 2008; Petroski and Deshaies, 2005) , we found that phosphatase treatment greatly reduced the interaction between Mdm2 and b-TRCP1 ( Figure 2E ), supporting the idea that Mdm2 interacts with b-TRCP1 in a phosphorylation-dependent manner.
Casein Kinase I Controls Mdm2 Stability It has been suggested that most b-TRCP1 downstream targets need to be properly modified by a combination of kinases within their degron sequences before their recognition and destruction by the SCF b-TRCP complex (Cardozo and Pagano, 2004; Jin et al., 2003) . We therefore sought to identify the kinase that phosphorylates Mdm2 and triggers its interaction with b-TRCP1. Examination of the Mdm2 protein sequence did not reveal a canonical
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCP degron sequence (DSGxxS) that could be recognized by the SCF b-TRCP E3 ligase complex (Cardozo and Pagano, 2004) . Thus, we used the PESTfinder program to identify two strong PEST sequences, which are typically associated with protein instability where putative degron sequences might reside, within the Mdm2 protein sequence ( Figure S3A ). The Scansite program predicted that most of the putative phosphorylation sites within these two PEST sequences are either CKI or casein kinase II (CKII) sites. Hence, we began to investigate the potential role of CKI or CKII in Mdm2 stability control.
In support of the notion that CKI is the upstream kinase triggering b-TRCP1-mediated Mdm2 destruction, we found that GST-Mdm2 cannot be recognized by b-TRCP1 in vitro unless it is phosphorylated by purified CKI, but not CKII ( Figure 3A) . Using coimmunoprecipitation and GST pull-down assays we found that Mdm2 interacted with CKIa1, CKIa2, CKId, and CKI3 ( Figures S3B and S3C ) (Winter et al., 2004) . We also detected the interaction between endogenous Mdm2 and endogenous CKId ( Figure 3B ), further supporting the physiological role of CKId in regulating Mdm2 stability. Consistent with this finding, overexpression of CKId and CKI3, and to less extent CKIa1 and CKIa2, reduced Mdm2 protein level ( Figure 3C ). On the other hand, expression of CKIg1 and CKIg2, or a kinase-dead mutant of CKId (K38R) (Peters et al., 1999) failed to promote Mdm2 destruction ( Figures S3E-S3G) .
Furthermore, inactivation of CKI by the small-molecule inhibitor D4476 (Rena et al., 2004) , resulted in accumulation of endogenous Mdm2 ( Figure 3D ) as well as a moderate increase in resistance to etoposide-induced Mdm2 destruction (Figure 3E ). Consistent with a role for CKI in Mdm2 stability control, inhibition of CKId activity by inhibitors ( Figure S3H ) or shRNA treatment ( Figure 3F ) significantly reduced the interaction between Mdm2 and b-TRCP1. Furthermore, depletion of CKI (mainly the CKId and CKI3 isoforms) led to elevated Mdm2 abundance (Figure 3G and Figures S3I and S3J) , and extended Mdm2 half-life (Figures S3K and S3L) , indicating that CKId and CKI3 might be the major isoforms regulating Mdm2 stability. DNA damage induced the interaction between endogenous Mdm2 and CKId ( Figure 3H ), providing a direct link between CKId and Mdm2 destruction after DNA damage response. In agreement with a previous report (Alsheich-Bartok et al., 2008) , we found that CKId resides in the cytoplasm in nonstressed cells, but in response to DNA damage, a significant fraction of endogenous CKId translocated into the nucleus ( Figures S3M and S3N ).
CKId Phosphorylates Mdm2 at Multiple Sites to Trigger Mdm2/b-TRCP1 Interaction
The absence of a canonical degron sequence in the Mdm2 protein sequence suggests that Mdm2 might contain multiple suboptimal degron sequences instead of one optimized degron. In support of this notion, using mass spectrometry analysis, we found that CKId phosphorylates GST-Mdm2 at multiple sites in vitro (Figures S4A and S4B) . In addition to the CKI sites we identified, Mdm2 has also been reported to be phosphorylated by CKI at multiple sites in vivo ( Figure S4D ) (Winter et al., 2004) . To further evaluate the physiological relevance of Mdm2 phosphorylation for its stability, we blocked the proteasome pathway with MG132 then analyzed the Mdm2 phosphorylation status with mass spectrometry. We found that proteasome inhibition resulted in increased phosphorylated Mdm2 species ( Figure S4C ), many of which overlapped with those identified in the in vitro CKId kinase assay ( Figure S4B ). Importantly, these phosphorylation sites resemble the DSGxxS degron site ( Figure S4E ).
Interestingly, the majority of the putative CKI sites reside in the two identified PEST sequences ( Figure S3A and Figures S4A-S4C). We named the PEST sequence containing the acidic domain the p2 region, and the PEST sequence containing the SQ cluster domain the p3 region ( Figure S3A and Figure S4A ). We noticed that the Ser121 site (DSGTSVS) identified by mass spectrometry residing outside the two PEST sequences, however, most resembles the canonical degron sequence (Figure S4F ). We named this region p1. To better understand the contribution of this putative degron to Mdm2 stability control, we developed phosphorylation-specific antibodies that recognize the phosphorylated state of Ser118 and Ser118/Ser121. Using these two antibodies, we demonstrated that these two sites were indeed phosphorylated in vivo ( Figures S4G-S4I ). Furthermore, inhibition of CKId by either CKI inhibitors or shRNA treatment led to a reduction in phosphorylation on both Ser118 and Ser121 of Mdm2 ( Figures S4J and S4K ). On the other hand, depletion of b-TRCP1 resulted in a dramatic increase of phosphorylation on both Ser118 and Ser121 of Mdm2 ( Figure S4K ).
Although phosphorylation of both Ser118 and Ser121 within the p1 region is sufficient for a Mdm2 peptide to interact with b-TRCP1 ( Figures S4L-S4N ), mutation or deletion of these two putative CKI phosphorylation sites did not abolish the ability of Mdm2 to interact with b-TRCP in vivo ( Figures S4O and S4P ), indicating that Mdm2 might contain additional b-TRCP recognition motifs. To further understand their contributions to Mdm2 destruction, we created a panel of Mdm2 mutants where the DSG site (p1), acidic domain (p2), and the SQ cluster (p3) regions were deleted individually or in combination ( Figure S4Q ). We also generated mutants wherein the potential critical Ser/Thr sites for individual suboptimal degrons, including some experimentally identified putative CKI phosphorylation sites, were pointmutated ( Figure 4A ; Figures S4E and S4R ). 
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCP Using in vitro kinase assays, we found that deletion of the p2 region greatly reduced the ability of CKId to phosphorylate Mdm2 ( Figure S4S ). We also found that deletion of either the p1 or p3 regions further reduced the phosphorylation by CKId, indicating that CKId also phosphorylates Mdm2 in the DSG and SQ cluster regions ( Figure S4S ). More interestingly, we observed a progressive reduction of the CKId-mediated phosphorylation after mutating the major phosphorylation sites identified by mass spectrometry analysis in a step-wise fashion ( Figure 4B ). These Mdm2 mutants interact with CKId with similar efficacy as the wild-type Mdm2 ( Figures S4T and S4U) , which indicates that the loss of phosphorylation of these mutants is not due to loss of their interaction with the CKId kinase. Altogether, these results support a possible model that CKId phosphorylates Mdm2 at multiple sites, which closely resembles the way GSK3 and PKA phosphorylate the Gli3 oncoprotein (Jia et al., 2005; Tempe et al., 2006) . Importantly, we found that the ability of various Mdm2 species to interact with b-TRCP1 correlated very well with their CKId phosphorylation status ( Figure 4C ; Figure S4V ). Taken together, this data indicates that phosphorylation of Mdm2 by CKId at multiple sites is critical for triggering the interaction of Mdm2 with b-TRCP.
CKId Phosphorylates Mdm2 at Multiple Sites to Trigger Mdm2 Destruction Next, we explored whether b-TRCP promotes Mdm2 destruction in a CKId phosphorylation-dependent manner. We found that the degree of decrease in CKId-mediated phosphorylation of the various Mdm2 mutants correlated with their resistance to b-TRCP-induced proteolysis ( Figures 5A and 5C) . Inactivation of the E3-ligase activity of Mdm2 by mutating its ring-finger domain (C464A) did not interfere with the ability of b-TRCP and CKId to degrade the Mdm2 protein ( Figure 5B ).
Degrons can serve to recruit E3 ligases when fused to artificial substrates. To test whether the identified Mdm2 degron sequences can function outside the context of Mdm2, the p1 See also Figure S4 .
Regulation of Mdm2 Turnover by CKI/SCFb-TRCP or p2 region was fused with the GST protein and their response to b-TRCP1-mediated protein degradation was examined. GSTp1 and GST-p2 were susceptible to b-TRCP-mediated destruction (Figures 5D and 5E ; Figure S5 ) whereas those with key CKI phosphorylation sites mutated or deleted were not ( Figure 5E ; Figure S5 ). These results strongly support the hypothesis that phosphorylation of Mdm2 by CKId at the p1 and p2 regions are both sufficient and required to trigger Mdm2 destruction.
Mdm2 Protein Abundance Is Controlled by Both Auto-and b-TRCP-Dependent Ubiquitination Pathways during Cell-Cycle Progression
In agreement with a previous report (Gu et al., 2003) , we found that Mdm2 C464A was more stable than WT-Mdm2 during the cell cycle ( Figure 6A ). However, Mdm2 C464A was still unstable in the early G1 phase. Importantly, the Dp1p2p3 mutant, which cannot be phosphorylated by CKId, was more stable than WT-Mdm2 in most cell-cycle phases and additional C464A mutation moderately increased its abundance ( Figure 6A ). These results suggest that both self-ubiquitination and b-TRCPmediated ubiquitination play important roles in mediating the timely destruction of Mdm2 during cell-cycle progression. However, Dp1p2p3/C464A was still unstable in certain cell-cycle phases, indicating that there might be additional unknown pathway(s) involved in Mdm2 stability control. The half-life of Mdm2 was greatly extended after inactivation of either self-ubiquitination (C464A-Mdm2) or b-TRCP-mediated (Dp1p2p3-Mdm2) ubiquitination ( Figure S6A ). Furthermore, depletion of endogenous b-TRCP via shRNA treatment resulted in a sharp increase in the abundance of both the wild-type and C464A mutant Mdm2 proteins ( Figure 6B ), indicating that both could still be degraded by the b-TRCP pathway.
b-TRCP Promotes Mdm2 Turnover and Ubiquitination
The observed progressive increase in Mdm2 stability after sequential mutation of multiple potential CKI sites ( Figure 5C ) might be due to inefficient b-TRCP-dependent proteolysis. In support of this idea, coexpression of CKId and b-TRCP1 resulted in a marked reduction in the half-life of wild-type (Figure 6C ) and Mdm2 C464A ( Figure S6B ), whereas it did not affect the half-life of the Dp1-23A ( Figure 6C ) and Dp1p2p3 Mdm2 mutants ( Figure S6B) . Importantly, the Dp1-23A Mdm2 mutant
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCP interacts with p53 similarly to wild-type Mdm2 ( Figure S6C ) and degrades p53 as efficiently as wild-type Mdm2 ( Figure S6D ). Collectively, these results indicate that these mutations did not alter the function of the Dp1-23A Mdm2 mutant, and that the observed stability increase in the Dp1p2p3 Mdm2 mutant might not be due to gross conformational changes. Consistent with this result, coexpression of CKId and b-TRCP promoted the ubiquitination of the Mdm2 C464A protein, but ubiquitination of the CKI-phosphorylation defective (Dp1p2p3) Mdm2 C464A mutant was greatly reduced ( Figure S6E ). More importantly, purified SCF/b-TRCP E3 ligase complex could promote the ubiquitination of GST-Mdm2
C464A protein in vitro in a CKI-phosphorylation-dependent manner, whereas its ability to ubiquitinate CKI-phosphorylationdefective Mdm2 C464A mutants (Dp1p2p3 and Dp1-23A) is significantly reduced ( Figure 6D ).
b-TRCP Promotes DNA DamageDependent Turnover of Mdm2 Next, we asked how manipulation of the b-TRCP-mediated Mdm2 destruction pathway affects p53 activity and its cellular functions in response to DNA damage. As shown in Figure 7A and Figures S7A and S7B , inactivation of b-TRCP partially blocked the destruction of Mdm2 in response to DNA damaging agents. Inactivation of CKId by shRNA treatment also partially blocked DNA damage-induced destruction of Mdm2 ( Figure S7B ). To further understand the role of b-TRCP1 in regulating the Mdm2/p53 pathway, we performed b-TRCP1 siRNA experiments in the U2OS cell line. As shown in Figure 7B , inactivation of b-TRCP led to increased Mdm2 abundance in the late G1-S phase, and this resulted in decreased p53 protein (Peschiaroli et al., 2006) and the p53's downstream targets, p21 and Bax ( Figure 7B ). Correspondingly, this resulted in elevated resistance to DNA damage-induced apoptosis (Figure 7C) . Using p53 À/À HCT116 cells or p53 siRNA-treated U2OS cells, we demonstrated that b-TRCP-depletion-induced resistance to apoptosis is partially through the p53 pathway ( Figures S7C-S7G ). Mdm2 might be required for this phenotype because further depletion of Mdm2 induced apoptosis in cells whose endogenous b-TRCP has been depleted (Figure 7C and Figures S7H and S7I) . However, the lack of a full recovery in the b-TRCP/Mdm2 double siRNA treated sample to levels of apoptosis observed in the Mdm2 single siRNA treated sample indicate that other potential b-TRCP1 substrate (s) (Ding et al., 2007) might also influence the ability of b-TRCP to regulate the cellular apoptotic pathway independent of Mdm2. Importantly, depletion of endogenous b-TRCP resulted in elevated Mdm2 expression in p53 À/À HCT116 cells as well, indicating that this process is p53-independent (Figure S7G) . Furthermore, consistent with increased Mdm2 expression, depletion of endogenous b-TRCP in WT-HCT116 cells resulted in reduced p53 and subsequent p21 expression ( Figure S7G ). As a result, it led to increased BrdU incorporation ( Figure S7J ) and a moderate increase in xenografted tumor growth ( Figure S7K) . Previous studies have revealed that p53 levels oscillate in MCF7 cells subjected to DNA damage (Batchelor et al., 2008; Hu et al., 2007) . These oscillations reflect pulsatile signaling of the ATM/ Chk2 pathway and negative feedback on p53 including the Mdm2-p53 feedback loop, wherein p53 induction by DNA damage is accompanied by increased Mdm2 expression, which in turn promotes subsequent p53 turnover. In this process, negative feedback by Mdm2 contributes to the reduction in p53 levels after the initial pulse, but is not sufficient to trigger continuous p53 pulses (Batchelor et al., 2008) . As expected, DNA damage resulted in oscillations of both p53 and Mdm2 expression in MCF7 cells ( Figure 7D ). Although the first p53 pulse after DNA damage was normal, depletion of b-TRCP resulted in increased Mdm2 levels and the second pulse of p53 was substantially reduced ( Figures  7D and 7E) . Furthermore, we found that inhibition of CKId by inhibitors ( Figure S7L ) or shRNA treatment ( Figure S7M ) also attenuated the p53 pulse in response to continuous DNA damage. Thus, CKId/SCF b-TRCP -dependent Mdm2 turnover contributes to the control of p53 dynamics in response to DNA damage that has been suggested to be important for the tumor suppressor function of p53 (Hu et al., 2007) .
DISCUSSION
The data presented here provides evidence for a molecular mechanism by which CKI-dependent phosphorylation of Mdm2
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCP at multiple sites triggers SCF b-TRCP -mediated Mdm2 destruction (Figure 8 ). It is well recognized that most F-box proteins, including b-TRCP, interact with their ubiquitin substrates only after they are properly phosphorylated (Petroski and Deshaies, 2005) . Therefore, the destruction of these substrates is regulated primarily at their phosphorylation by appropriate kinases. In the case of Mdm2, specific CKI isoforms control the timing of Mdm2 turnover. In support of this idea, blocking CKI activity resulted in a marked increase in the steady-state abundance of Mdm2. It is known that CKI activity is subject to many layers of regulation (Giamas et al., 2007; Knippschild et al., 2005; Swiatek et al., 2004) . Here we report the nuclear localization of CKId and its interaction with Mdm2 was enhanced in response to DNA damage. However, additional studies are required to fully understand the molecular mechanisms by which CKId activity is regulated in response to DNA damage and during cell-cycle progression.
We demonstrated that the major CKI phosphorylation sites are located in the Mdm2 acidic domain (p2), whereas other minor CKI sites are located in the N-terminal DSG site (p1) and the C-terminal SQ cluster (p3) region. More interestingly, sequential inactivation of the potentially critical Ser/Thr sites for suboptimal degrons in Mdm2 resulted in a progressive reduction of CKI-mediated phosphorylation ( Figure 4B ), which correlated well with reduced interaction of Mdm2 with b-TRCP1 ( Figure 4C) , and reduced destruction of Mdm2. Furthermore, individual mutation of each phosphorylation site did not show considerable protection against b-TRCP1/CKId-mediated destruction (data not shown). This suggests that, in contrast to many known b-TRCP1 substrates that contain one optimized canonical degron sequence, such as Emi-1 or Claspin, the Mdm2 protein contains many suboptimal degron sequences that are phosphorylated by CKI. Other b-TRCP1 substrates, including Cdc25A (Kanemori et al., 2005) and Gli3 (Pan et al., 2006; Tempe et al., 2006; Wang and Li, 2006) , are also known to contain multiple degron sequences. A similar mechanism has been described for SCF Cdc4 -dependent turnover of the Sic1 Cdk inhibitor (Nash et al., 2001) . Multisite phosphorylation likely represents a more general mechanism for creating switch-like transitions via SCFdependent turnover pathways (Ferrell, 2001; Harper, 2002) . Our studies suggested that the cumulative, multisite phosphorylation of Mdm2 by CKId might set up a switch for Mdm2 destruction in response to DNA damage and during the cell cycle.
It was reported previously that Mdm2 auto-ubiquitination plays an important role in DNA-damage triggered Mdm2 destruction (Stommel and Wahl, 2004) . However, in agreement with a recent report (Itahana et al., 2007) , as efficiently as the wild-type Mdm2 ( Figure 5B ). These findings suggest that CKImediated phosphorylation, rather than the ring-finger domain, might be critical for Mdm2 destruction after DNA damage. Nevertheless, Mdm2 auto-ubiquitination also plays a critical role in regulating the steady state level of Mdm2 during the cell cycle, as Mdm2 C464A was more stable than wild-type Mdm2 in synchronous cell-cycle release experiments ( Figure 6A ). Consistent with gain-of-function experiments, depletion of b-TRCP1 also stabilized Mdm2 C464A ( Figure 6B ). Taken together, these data indicate that constitutive Mdm2 destruction during the cell cycle is tightly regulated by both auto-ubiquitination and b-TRCP1-mediated ubiquitination pathways. Mdm2 is an oncoprotein that is frequently overexpressed in tumors, which enhances cellular transformation (Momand et al., 2000) . Although amplification of the mdm2 locus has been found in some cases, the molecular mechanism leading to elevated Mdm2 expression in most tumors remains unclear. Our studies suggested that disruption of the Mdm2 destruction pathway could potentially contribute to increased Mdm2 abundance. This could be achieved by inactivation of its E3 ligase b-TRCP1 (Frescas and Pagano, 2008; Nakayama and Nakayama, 2005) , inactivation of its modifying enzyme CKI, or by acquiring mutations that disrupt its phosphorylation by CKI. Similarly, both c-myc gene amplification and mutations within the degron sequence are thought to contribute to c-Myc overexpression in cancers (Welcker et al., 2004) . In this regard, it is interesting that alterations in b-trcp1 have been reported in many types of cancers (Nakayama and Nakayama, 2005) . Our data suggest that a compromised Mdm2 destruction pathway might lead to enhanced Mdm2 oncogenic activity by promoting p53 destruction and thus facilitating tumor progression. Further studies may reveal the extent to which the CKI/b-TRCP pathway and its linkage to Mdm2 is disrupted in cancer.
EXPERIMENTAL PROCEDURES siRNAs
Human siRNA oligo that can deplete both b-TRCP1 and b-TRCP2 (sense, 5 0 -AAGUGGAAUUUGUGGAACAUC-3 0 ) has been validated previously 
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCP (Jin et al., 2003) and was purchased from Dharmacon. Human siRNA oligos against Cullin-1, Fbw7, Skp2, and Cdh1 have been described previously (Benmaamar and Pagano, 2005; Wei et al., 2004; Wei et al., 2005) . Human siRNA oligos that can deplete Mdm2 (Mdm2: sense, 5 0 -AAGCCATTGCTTTT GAAGTTA-3 0 ), or p53 (sense, 5 0 -AAGGATGCCCAGGCTGGGAAG-3 0 ) were purchased from Dharmacon. Luciferase GL2 siRNA oligo was purchased from Dharmacon. As described previously, siRNA oligos were transfected into subconfluent cells using Oligofectamine or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions (Wei et al., 2004; Wei et al., 2005) . Transient transfection of the control and b-TRCP siRNA oligos into MCF7 cells was performed according to the manufacturer's instructions (Amaxa Biosystems).
Cell Culture and Cell Synchronization
Cell culture including synchronization and transfection have been described (Wei et al., 2004) . To perform U2OS cell synchronization, 2 mM hydroxyurea was added into U2OS cells cultured at subconfluence (around 20%-25%) to arrest cells at the late G1 phase. After 18 hr, cells were washed three times with warm PBS and then freshly made DMEM medium containing 10% FBS was added. Lentiviral shRNA virus packaging and subsequent infection was performed as described previously (Boehm et al., 2005) .
Xenografted Tumor Growth Assays
Six-week-old female nude mice (Taconic) were used for xenograft studies. Approximately 1.5 3 10 6 viable tumor cells were resuspended in 50 ml PBS solution and injected subcutaneously into the mice (n = 6 mice for each group) and the bioluminescent imaging and normalization were performed as described previously (Zhang et al., 2009) . Briefly, for bioluminescent detection and quantification of the xenografted tumor cells, mice were given a single intraperitoneal injection of a mixture of luciferin (50 mg/kg), ketamine (150 mg/kg), and xylazine (12 mg/kg) in sterile water. Five minutes later, mice were placed in a light-tight chamber equipped with a charge-coupled device IVIS imaging camera (Xenogen). Photons were collected for a period of 1-60 s, and images were obtained by using LIVING IMAGE 2.60.1 software (Xenogen) and quantified using IGOR Pro 4.09A image analysis software (WaveMatrics). The total photons from the b-TRCP1 shRNA tumor region of interest (ROI) were divided by the total photons from GFP shRNA tumor ROI and, for each mouse, normalized based on the natural log of the ratio of the initial bioluminescent imaging (day 0) for that mouse. Results were presented as mean ± standard error of the mean (SEM). All mice experiments were approved by the Harvard University and Dana-Farber Cancer Institute Institutional Animal Care and Use Committee, and the experiments were performed according to the relevant regulatory standards.
Mdm2 Binding Assays
Binding to immobilized GST proteins was performed as described before (Wei et al., 2004) . Where indicated, the GST-Mdm2 proteins were incubated with CKI in the presence of ATP for 1 hr before the binding assays.
In Vitro Kinase Assay CKI was purchased from New England BioLabs. The CKI in vitro kinase assays were performed according to the manufacturer's instructions (New England Biolab). Briefly, 5 mg of indicated GST fusion proteins were incubated with purified active CKI in the presence of 5 mCi [g-32 P] ATP and 200 mM cold ATP in the CKI reaction buffer for 15-30 min. The reaction was stopped by the addition of SDS-containing lysis buffer, resolved on SDS-PAGE, and detected by autoradiography.
In Vitro Ubiquitination Assay
The in vitro ubiquitination assays were performed as described previously . To purify SCF/b-TRCP1 complex, 293T cells were transfected with vectors encoding GST-b-TRCP1, Myc-Cul-1, Myc-Skp1, and HA-Rbx1. The SCF/b-TRCP1 (E3) complexes were purified from the whole-cell lysates using GST-agarose beads. Before the in vitro ubiquitination assay, indicated GST-Mdm2 proteins were incubated with purified, recombinant active CKId in the presence of ATP (with kinase reaction buffer as a negative control) in 30 C for 30 min. Afterwards, the kinase reaction products were incubated with purified SCF/b-TRCP1 (E3) complexes in the presence of purified, recombinant active E1, E2 (UbcH5a and UbcH3), ATP, and ubiquitin. The reactions were stopped by the addition of 23 SDS-PAGE sample buffer and the reaction products were resolved by SDS-PAGE gel and probed with the indicated antibodies. Additional experimental procedures are included in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, Supplemental References, seven figures and can be found with this article online at doi:10.1016/j.ccr.2010.06.015.
